LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) CEO George Lemaitre sold 27,881 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
LeMaitre Vascular Stock Down 5.8%
Shares of NASDAQ:LMAT traded down $6.30 during midday trading on Monday, reaching $101.64. 410,363 shares of the company were exchanged, compared to its average volume of 209,885. LeMaitre Vascular, Inc. has a fifty-two week low of $78.35 and a fifty-two week high of $118.01. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $110.00 and a two-hundred day simple moving average of $94.48. The firm has a market cap of $2.32 billion, a PE ratio of 37.51, a P/E/G ratio of 3.00 and a beta of 0.60.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. During the same period last year, the business posted $0.48 earnings per share. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.
LeMaitre Vascular Announces Dividend
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after acquiring an additional 21,946 shares during the period. Conestoga Capital Advisors LLC grew its position in shares of LeMaitre Vascular by 3.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock valued at $161,224,000 after acquiring an additional 51,825 shares during the period. First Trust Advisors LP grew its position in shares of LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after acquiring an additional 111,193 shares during the period. State Street Corp grew its position in shares of LeMaitre Vascular by 0.8% in the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after acquiring an additional 6,130 shares during the period. Finally, Congress Asset Management Co. grew its position in shares of LeMaitre Vascular by 5.8% in the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after acquiring an additional 40,065 shares during the period. Institutional investors own 84.64% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on LMAT shares. Roth Mkm reaffirmed a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Wells Fargo & Company raised their target price on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. Citizens Jmp raised their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus target price of $112.60.
Get Our Latest Stock Analysis on LeMaitre Vascular
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Featured Stories
- Five stocks we like better than LeMaitre Vascular
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
